Edition:
United States

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

142.10USD
4:00pm EDT
Change (% chg)

$2.60 (+1.86%)
Prev Close
$139.50
Open
$139.04
Day's High
$142.79
Day's Low
$138.00
Volume
658,685
Avg. Vol
305,390
52-wk High
$148.50
52-wk Low
$42.63

Latest Key Developments (Source: Significant Developments)

Dexcom Acquires TypeZero Technologies
Wednesday, 22 Aug 2018 04:05pm EDT 

Aug 22 (Reuters) - DexCom Inc ::DEXCOM ACQUIRES TYPEZERO TECHNOLOGIES.DEXCOM INC - TERMS OF TRANSACTION WERE NOT DISCLOSED..DEXCOM INC - EXPECTS TO SUPPORT FIRST COMMERCIAL LAUNCH OF AN AID SYSTEM USING INCONTROL ALGORITHM IN 2019.  Full Article

FDA Authorizes Marketing Of New Dexcom G6 CGM Eliminating Need For Fingerstick Blood Testing
Tuesday, 27 Mar 2018 04:45pm EDT 

March 27 (Reuters) - Dexcom Inc ::FDA AUTHORIZES MARKETING OF THE NEW DEXCOM G6® CGM ELIMINATING NEED FOR FINGERSTICK BLOOD TESTING FOR PEOPLE WITH DIABETES.DEXCOM INC - EXPECTS TO LAUNCH DEXCOM G6 CGM SYSTEMLATER THIS YEAR.  Full Article

U.S. FDA Says Permitted Marketing Of Dexcom G6 Integrated Continuous Glucose Monitoring System
Tuesday, 27 Mar 2018 03:29pm EDT 

March 27 (Reuters) - Dexcom Inc ::U.S. FDA SAYS PERMITTED MARKETING OF THE DEXCOM G6 INTEGRATED CONTINUOUS GLUCOSE MONITORING (ICGM) SYSTEM.U.S. FDA SAYS AUTHORIZATION OF ICGM SYSTEM CLASSIFIES THIS NEW TYPE OF DEVICE IN CLASS II & SUBJECTS IT TO CERTAIN CRITERIA CALLED SPECIAL CONTROLS.  Full Article

Waveform Technologies Receives Favorable Decision On Critical Glucose Monitoring Patents
Thursday, 8 Mar 2018 01:36pm EST 

March 8 (Reuters) - Waveform Technologies::SAYS ‍PTAB RULED 2 EARLY PATENTS HELD BY WAVEFORM ARE NOT INVALID, BASED ON CHALLENGES BROUGHT BY DEXCOM​.SAYS RECEIVES FAVORABLE DECISION ON CRITICAL GLUCOSE MONITORING PATENTS.  Full Article

Dexcom Inc Q4 GAAP Loss Per Share $0.11
Tuesday, 27 Feb 2018 04:01pm EST 

Feb 27 (Reuters) - Dexcom Inc ::DEXCOM REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS.Q4 GAAP LOSS PER SHARE $0.11.Q4 NON-GAAP EARNINGS PER SHARE $0.10 EXCLUDING ITEMS.Q4 REVENUE ROSE 29 PERCENT TO $221 MILLION.SEES FY 2018 REVENUE $830 MILLION TO $850 MILLION.  Full Article

DexCom Says Preliminary Q4 Revenue Was $218 Mln
Monday, 8 Jan 2018 04:05pm EST 

Jan 8 (Reuters) - DexCom Inc ::DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2017 AND PROVIDES INITIAL 2018 OUTLOOK.SEES FY 2018 REVENUE ABOUT $830 MILLION TO $850 MILLION.SEES FY 2017 REVENUE ABOUT $715 MILLION.PRELIMINARY Q4 REVENUE $218 MILLION VERSUS I/B/E/S VIEW $212.6 MILLION .FY2017 REVENUE VIEW $710.2 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $854.6 MILLION -- THOMSON REUTERS I/B/E/S.Q4 REVENUE VIEW $212.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Dexcom announces development agreement with Lilly
Tuesday, 21 Nov 2017 10:33am EST 

Nov 21 (Reuters) - Dexcom Inc ::Dexcom announces development agreement with Lilly to integrate Dexcom CGM into connected diabetes ecosystem.Says ‍companies expect to combine Lilly's smart insulin delivery devices and Dexcom CGM.  Full Article

Dexcom Inc reports Q3 GAAP loss per share $0.02
Wednesday, 1 Nov 2017 04:01pm EDT 

Nov 1 (Reuters) - Dexcom Inc :Dexcom, inc. Reports record third quarter 2017 financial results.Q3 non-gaap loss per share $0.04.Q3 gaap loss per share $0.02.Q3 revenue $184.6 million versus i/b/e/s view $184.2 million.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost
Tuesday, 24 Oct 2017 04:30pm EDT 

Oct 24 (Reuters) - Tandem Diabetes Care Inc ::‍Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers​.Tandem diabetes care inc - ‍tandem and Dexcom are now extending terms of their welcome programs for animas customers through march 31, 2018​.  Full Article

‍Janus Henderson reports 10.2 pct passive stake in Dexcom
Wednesday, 11 Oct 2017 06:08am EDT 

Oct 11 (Reuters) - ‍Janus Henderson Group PLC:‍Janus Henderson Group PLC reports a 10.2 percent passive stake in Dexcom Inc as of sept 30 - SEC filing​.  Full Article

BRIEF-DexCom Reports Q1 GAAP Loss Per Share Of $0.28

* Q1 REVENUE $184.4 MILLION VERSUS I/B/E/S VIEW $172.3 MILLION